Back to Search Start Over

The Emerging Pathogen Candida auris: Growth Phenotype, Virulence Factors, Activity of Antifungals, and Effect of SCY-078, a Novel Glucan Synthesis Inhibitor, on Growth Morphology and Biofilm Formation

Authors :
Larkin, Emily
Hager, Christopher
Chandra, Jyotsna
Mukherjee, Pranab K.
Retuerto, Mauricio
Salem, Iman
Long, Lisa
Isham, Nancy
Kovanda, Laura
Borroto-Esoda, Katyna
Wring, Steve
Angulo, David
Ghannoum, Mahmoud
Source :
Antimicrobial Agents and Chemotherapy; March 2017, Vol. 61 Issue: 5
Publication Year :
2017

Abstract

ABSTRACTCandidaauris, a new multidrug-resistant Candidaspp. which is associated with invasive infection and high rates of mortality, has recently emerged. Here, we determined the virulence factors (germination, adherence, biofilm formation, phospholipase and proteinase production) of 16 C. aurisisolates and their susceptibilities to 11 drugs belonging to different antifungal classes, including a novel orally bioavailable 1,3-β-d-glucan synthesis inhibitor (SCY-078). We also examined the effect of SCY-078 on the growth, ultrastructure, and biofilm-forming abilities of C. auris. Our data showed that while the tested strains did not germinate, they did produce phospholipase and proteinase in a strain-dependent manner and had a significantly reduced ability to adhere and form biofilms compared to that of Candida albicans(P= 0.01). C. aurisisolates demonstrated reduced susceptibility to fluconazole and amphotericin B, while, in general, they were susceptible to the remaining drugs tested. SCY-078 had an MIC90of 1 mg/liter against C. aurisand caused complete inhibition of the growth of C. aurisand C. albicans. Scanning electron microscopy analysis showed that SCY-078 interrupted C. auriscell division, with the organism forming abnormal fused fungal cells. Additionally, SCY-078 possessed potent antibiofilm activity, wherein treated biofilms demonstrated significantly reduced metabolic activity and a significantly reduced thickness compared to the untreated control (P< 0.05 for both comparisons). Our study shows that C. aurisexpresses several virulence determinants (albeit to a lesser extent than C. albicans) and is resistant to fluconazole and amphotericin B. SCY-078, the new orally bioavailable antifungal, had potent antifungal/antibiofilm activity against C. auris, indicating that further evaluation of this antifungal is warranted.

Details

Language :
English
ISSN :
00664804 and 10986596
Volume :
61
Issue :
5
Database :
Supplemental Index
Journal :
Antimicrobial Agents and Chemotherapy
Publication Type :
Periodical
Accession number :
ejs41797787
Full Text :
https://doi.org/10.1128/AAC.02396-16